ATOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ATOS is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some positive event-driven momentum from recent trial data and FDA designation, but the current setup lacks a clean technical buy signal, options sentiment is extremely bullish but thin, and the company remains unprofitable with no meaningful revenue. Since the user is impatient and does not want to wait for an optimal entry, my direct view is to avoid buying this now and wait for a clearer trend or stronger fundamental validation.
The current trend is mixed to weak. Price closed at 5.543, below the previous close of 5.67, with regular market change at -2.24%. MACD histogram is slightly negative and still expanding lower, which suggests momentum is soft. RSI_6 is 53.08, neutral, so there is no oversold setup. Moving averages are converging, which usually indicates indecision rather than a strong uptrend. Key levels to watch are support at 5.243 and resistance at 6.021. The stock is sitting below pivot at 5.632, so technically it is not confirming strength right now.
["May 6: KARISMA trial results showed low-dose Endoxifen significantly reduced mammographic density, supporting a breast cancer risk-reduction angle.", "May 4: FDA Rare Pediatric Disease designation for (Z)-endoxifen in McCune-Albright Syndrome could create upside optionality, including potential Priority Review Voucher value if approved.", "News flow is clearly positive and event-driven, which can attract speculative buying."]
["The company remains unprofitable with Q4 2025 net income of -$10.94M and EPS of -1.27.", "Revenue is still 0, so there is no commercial growth base supporting valuation.", "MACD is negative and price is below the pivot level, showing no strong technical confirmation.", "No recent insider, hedge fund, or congress trading trends are signaling accumulation.", "No AI Stock Picker or SwingMax buy signal is present today."]
In 2025/Q4, Atossa reported revenue of 0, unchanged in practical terms, so there is no top-line operating growth yet. Net income was -$10.94M, improved 72.32% year over year, and EPS was -1.27, also improved 69.33% year over year. The quarter shows reduced losses, but the company is still deeply unprofitable and not yet generating sales.
Analyst sentiment is still constructive but mixed on targets. H.C. Wainwright kept a Buy rating and raised its target to $25 from $7, with the change driven by the 1-for-15 reverse split. Craig-Hallum also kept a Buy rating but cut its target sharply to $10 from $35 after Atossa paused Z-endoxifen development in metastatic breast cancer to focus on other programs. Overall, Wall Street pros remain positive on the story, but target cuts show caution about execution and program prioritization.
